Adagene IncNASDAQ:ADAG
- LAST PRICE1.9250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.8800/ 1
- Ask / Lots1.9600/ 56
- Open / Previous Close1.9900 / 1.9250
- Day Range
- 52 Week Range
- Volume19,094
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADAG |
|---|---|---|
| 09:32 ET | 162 | 1.99 |
| 09:33 ET | 6132 | 1.89 |
| 09:35 ET | 100 | 1.8701 |
| 09:37 ET | 1080 | 1.9709 |
| 09:39 ET | 600 | 1.9 |
| 09:44 ET | 400 | 1.9 |
| 09:50 ET | 100 | 1.88 |
| 09:55 ET | 100 | 1.915 |
| 10:26 ET | 200 | 1.88 |
| 10:44 ET | 100 | 1.88 |
| 10:56 ET | 250 | 1.88 |
| 11:00 ET | 1049 | 1.91 |
| 11:07 ET | 313 | 1.935 |
| 11:20 ET | 100 | 1.9599 |
| 12:03 ET | 100 | 1.9101 |
| 12:10 ET | 2571 | 1.91 |
| 12:12 ET | 100 | 1.91 |
| 12:51 ET | 100 | 1.91 |
| 01:06 ET | 100 | 1.92 |
| 01:45 ET | 2100 | 1.91 |
| 01:47 ET | 200 | 1.91 |
| 01:49 ET | 200 | 1.91 |
| 01:56 ET | 900 | 1.9499 |
| 02:14 ET | 100 | 1.9101 |
| 02:25 ET | 140 | 1.92 |
| 03:14 ET | 200 | 1.925 |
| 03:44 ET | 100 | 1.925 |
Jan 24, 2023
Morgan Stanley Adjusts Price Target on Adagene to $5 From $7, Maintains Overweight Rating, from 8:52AM ET on Tuesday Jan 24, 2023 by MT Newswires
8:52AM ET on Tuesday Jan 24, 2023 by MT Newswires
Jan 9, 2023
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody(R) ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial, from 7:00AM ET on Monday Jan 09, 2023 by GlobeNewswire
7:00AM ET on Monday Jan 09, 2023 by GlobeNewswire
Jan 5, 2023
Adagene to Present at the Biotech Showcase(TM) 2023 in San Francisco on January 9, from 4:01PM ET on Thursday Jan 05, 2023 by GlobeNewswire
4:01PM ET on Thursday Jan 05, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adagene Inc | 81.2M | -1.0x | --- |
Curis Inc | 73.2M | -1.2x | --- |
Ambrx Biopharma Inc | 77.6M | -0.8x | --- |
Sellas Life Sciences Group Inc | 71.0M | -1.5x | --- |
Compugen Ltd | 75.9M | -1.9x | --- |
Adverum Biotechnologies Inc | 69.8M | -0.4x | --- |
Company Information
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Contact Information
- Headquarters
- 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial ParkSUZHOU, JNG, China 215123
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Peter Luo
- Chief Financial Officer, Director
- Tam Man Kin
- Executive Vice President of Clinical Development
- Zha Jiping
- Senior Vice President of Global Regulatory Affairs
- Shang Jin
- Senior Vice President, Head of Clinical Operations
- She Xiaohong
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $81.2M |
|---|---|
Revenue (TTM) | $12.7M |
Shares Outstanding | 34.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.92 |
Book Value | $3.58 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 6.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -651.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
